☆ 4.7 Article

Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis

Zhiying He et al.

Summary: In decompensated patients with HBV-related cirrhosis, disease progression can be altered or reversed with antiviral therapy. However, little is known about the stable re-compensation in these patients. The study found that about 40% of patients in the immediate-treatment group were able to maintain stable re-compensation during 6 years of antiviral therapy.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

添加到收藏夹

Article Immunology

Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Guanghua Rong et al.

Summary: Addition of Biejia-Ruangan (BR) to the current standard treatment with entecavir (ETV) can significantly increase rates of fibrosis regression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis.

JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy

Tae Hyung Kim et al.

Summary: The study identified six clinical parameters, including alpha-fetoprotein and timing of antiviral therapy, which were combined into a scoring system to accurately predict early re-compensation in patients with HBV-related decompensated cirrhosis.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Baveno VII - Renewing consensus in portal hypertension

Roberto de Franchis et al.

Summary: The Baveno VII workshop focused on personalized care for portal hypertension in patients with compensated cirrhosis or cACLD, discussing various aspects including diagnosis, treatment, and prevention measures in 9 main topics, resulting in a series of consensus recommendations.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Virology

Current Trend in Antiviral Therapy for Chronic Hepatitis B

Rong-Nan Chien et al.

Summary: The goal of treating chronic hepatitis B is to suppress HBV replication to prevent liver damage and complications. Currently, pegylated interferon, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide are the first-line treatment options. Finite NUC therapy has shown promise in increasing the rate of HBsAg loss in HBeAg-negative patients.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Towards a new definition of decompensated cirrhosis

Gennaro D'Amico et al.

Summary: There is a consensus that clinical complications indicate the transition from compensated to decompensated cirrhosis. Decompensation significantly worsens patient prognosis and is a key factor in predicting mortality. Decompensated cirrhosis can follow two distinct pathways: acute and non-acute, with acute decompensation often representing further deterioration.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China

Mei Liu et al.

Summary: This study examined the gender differences in demographic and clinical characteristics of patients with hepatitis B virus (HBV)-related liver diseases. The results showed that being employed, having a lower personal monthly income, being current alcohol users, having cirrhosis or hepatocellular carcinoma, and experiencing less severe insomnia were independently associated with male gender. In addition, later onset of HBV-related diseases and older age were also independently associated with male gender.

PEERJ (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis

Qi Wang et al.

Summary: The study validates the Baveno VII definition of recompensation and explores the criteria for stable improvement of liver function tests in entecavir-treated patients with CHB-related decompensated cirrhosis. The study shows that over 50% of patients with hepatitis B-related decompensated cirrhosis treated with antivirals could recompensate and proposes laboratory criteria which could be used to define recompensation.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study

Brian J. McMahon et al.

Summary: The study revealed a strong association between HBV genotype and HCC occurrence, with genotypes F, C, and A posing higher risks. HBV genotype should be taken into consideration for risk stratification.

HEPATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study

Xiaomei Xu et al.

Summary: This study aimed to evaluate recompensation factors among patients with decompensated cirrhosis, finding that albumin, total protein, hemoglobin, basophil percentage, alanine aminotransferase, neutrophil-to-lymphocyte ratio, and diabetes are key indicators for identifying recompensation. The decision tree model developed had a high accuracy rate, specificity, and sensitivity in distinguishing patients with recompensated cirrhosis. These simple variables may aid clinicians in developing treatment plans to promote recompensation in patients with decompensated cirrhosis.

BMJ OPEN (2021)

添加到收藏夹

Review Microbiology

Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy

Mindie H. Nguyen et al.

CLINICAL MICROBIOLOGY REVIEWS (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges

Hong Zhao et al.

BIOMED RESEARCH INTERNATIONAL (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?

Amr Shaaban Hanafy et al.

HEPATOLOGY INTERNATIONAL (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis

Jeong Won Jang et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

How can we improve the performance of Model for End-Stage Liver Disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment?

Tae Hyung Kim et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)

添加到收藏夹

Correction Gastroenterology & Hepatology

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis (vol 69, pg 406, 2018)

Paolo Angeli et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Review Immunology

Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis: Is the Point of No Return the Same Before and After Liver Transplantation? A Review

Carmen Vinaixa et al.

TRANSPLANTATION (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants

Chih-Lin Lin et al.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people

Lance K. Ching et al.

LIVER INTERNATIONAL (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis

Mauro Bernardi et al.

JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy of Lamivudine Combined With Adefovir Dipivoxil Versus Entecavir Monotherapy in Patients With Hepatitis B-Associated Decompensated Cirrhosis: A Meta-Analysis

Hong Peng et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2014)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

The clinical course of cirrhosis. Population based studies and the need of personalized medicine

Gennaro D'Amico

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management

Ming-Ling Chang et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

Patrick Marcellin et al.

LANCET (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

Jiang-Shan Lian et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis

A. K. Singal et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)

添加到收藏夹

Review Gastroenterology & Hepatology

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies

G D'Amico et al.

JOURNAL OF HEPATOLOGY (2006)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of patients with decompensated HBV cirrhosis

RJ Fontana

SEMINARS IN LIVER DISEASE (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.